Grifols (GRFS) Total Liabilities (2009 - 2025)
Grifols (GRFS) posted Total Liabilities of $14.1 billion for Q4 2025, up 3.06% quarter-over-quarter from $13.7 billion in Q4 2024, and up 3.06% year-on-year from $13.7 billion in Q4 2024.
Grifols (GRFS) Total Liabilities (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Total Liabilities for 16 consecutive years, with $14.1 billion the latest figure, recorded in Q4 2025.
- Total Liabilities for Q4 2025 came in at $14.1 billion, up 3.06% year-over-year; the trailing twelve-month figure through Dec 2025 was $14.1 billion (up 3.06% YoY), and the FY2025 annual result was $14.1 billion, up 13584.86% from the prior year.
- Total Liabilities was $14.1 billion for Q4 2025 at Grifols, up from $13.7 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $14.5 billion in Q4 2023 and troughed at $13.5 billion in Q4 2022.
- Average Total Liabilities over 5 years is $13.9 billion, with a median of $13.7 billion recorded in 2024.
- Year-over-year, Total Liabilities surged 33.65% in 2021 and slipped 5.69% in 2024.
- Over 5 years, Total Liabilities stood at $13.6 billion in 2021, then declined by 0.81% to $13.5 billion in 2022, then grew by 7.25% to $14.5 billion in 2023, then decreased by 5.69% to $13.7 billion in 2024, then climbed by 3.06% to $14.1 billion in 2025.
- Per Business Quant data, the three most recent Total Liabilities figures were $14.1 billion in Q4 2025, $13.7 billion in Q4 2024, and $14.5 billion in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 85.38 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.71 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 143.12 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -66.63 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 82.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | 14.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 13.68 Bn |
| Dec 31, 2023 | 14.50 Bn |
| Dec 31, 2022 | 13.52 Bn |
| Dec 31, 2021 | 13.63 Bn |
| Dec 31, 2020 | 10.20 Bn |
| Dec 31, 2019 | 9.63 Bn |
| Dec 31, 2018 | 8.88 Bn |
| Jun 30, 2018 | 8.91 Bn |
| Dec 31, 2017 | 8.58 Bn |
| Jun 30, 2017 | 8.28 Bn |
| Dec 31, 2016 | 6.91 Bn |
| Sep 30, 2016 | 6.74 Bn |
| Jun 30, 2016 | 6.92 Bn |
| Mar 31, 2016 | 100.59 Mn |
| Dec 31, 2015 | 6.91 Bn |
| Sep 30, 2015 | 6.65 Bn |
| Mar 31, 2015 | 7.05 Bn |
| Dec 31, 2014 | 7.23 Bn |
| Sep 30, 2014 | 7.38 Bn |